TetraLogic Pharmaceuticals has an experienced management team with complementary expertise in research and development, clinical development, commercialization, finance and operations management. Together, the team has significant leadership capabilities for building a successful biopharmaceutical company.
J. Kevin Buchi, MBA
President and Chief Executive Officer
Mr. Buchi was most recently Corporate Vice President, Global Branded Products, at Teva Pharmaceutical Industries Ltd. Prior to joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva for $8 billion in October 2011. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon’s Chief Executive Officer in December 2010. He graduated from Cornell University with a Bachelor of Arts degree in chemistry and received a Master of Management degree from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Buchi is a Certified Public Accountant.
C. Glenn Begley, M.B.B.S, PhD, F.R.A.C.P., F.R.C.P.A., F.R.C.Path.
Chief Scientific Officer and Senior Vice President, Research & Development
Until January 2012, Dr. Begley was Vice-President and Global Head of Hematology and Oncology Research at Amgen Inc. He joined Amgen in 2002, and was responsible for building the Hematology and Oncology research program. He also had scientific responsibility for marketed Amgen products which involved preparation and presentations at multiple FDA face-to-face meetings and FDA Drug Advisory Committee meetings. Before joining Amgen, he had over 20 years of clinical experience in medical oncology and hematology. His early studies first described human G-CSF, and in later clinical studies, he first demonstrated that G-CSF-"mobilized" blood stem cells hastened hematopoietic recovery compared with bone marrow transplantation. This finding revolutionized the approach to clinical hematopoietic cell transplantation. His basic research focused on hematopoietic regulation. He defined the function of the CSFs and their receptors using animal models. He was the first to molecularly clone the transcription factor SCL, and demonstrate its critical role in leukemia and normal hematopoiesis. Dr. Begley is Board Certified in Australia as a Medical Oncologist (F.R.A.C.P.), Laboratory Hematologist (F.R.C.P.A., Australia; F.R.C.Path, United Kingdom) and has a Ph.D. in cellular and molecular biology. He has published over 200 scientific papers and was elected to the prestigious Association of American Physicians in 2008.
Stephen M. Condon, PhD
Vice President, Chemistry
Dr. Condon is Vice President for Chemistry at TetraLogic Pharmaceuticals. Prior to joining TetraLogic Pharmaceuticals in 2004, Dr. Condon was a Group Leader in medicinal chemistry at ViroPharma Corporation where he was involved in the discovery and development of inhibitors of hepatitis C NS5B RNA-dependent RNA polymerase. From 1995-2000, Dr. Condon was a member of the medicinal chemistry group at Rhône-Poulenc Rorer where his work led to the discovery of number of highly active anabolic agents for the treatment of post-menopausal osteoporosis and the elucidation of the bioactive conformation of human parathyroid hormone. In 1994, Dr. Condon received his doctoral degree with Professor Amos B. Smith III at the University of Pennsylvania after completing the total syntheses of rapamycin and demethoxyrapamycin.
Tony Meehan, PhD, MBA
Vice President, Alliance Management and Operations
Dr. Meehan has been working with both large pharma and small start-up firms for over 20 years. He was most recently Sr. Director of New Venture Development with RedScript Ventures, LLC, an internal venturing group with Johnson & Johnson. Prior to that, as Director of Drug Product Development, he led a group of 50 scientists that supported over 40 investigational drug programs for Janssen Pharmaceuticals. He came to Janssen in 2005 through the acquisition of TransForm Pharmaceuticals, where he was Director of Pharmaceutical Development, and played a leadership role in building TransForm’s product pipeline. During his eleven years with Merck & Co., Tony contributed to the development and launch of eight commercial drug and vaccine products. Tony has a BSE in chemical engineering from the University of Pennsylvania, a Ph.D. in chemical engineering from Carnegie Mellon University, and an M.B.A. from the Wharton School of the University of Pennsylvania.
Pete A. Meyers, MBA
Chief Financial Officer
Mr. Meyers was most recently Managing Director, Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. He joined Deutsche Bank in 2005 after serving six years with Credit Suisse First Boston LLC where he was a Managing Director in Health Care Investment Banking specializing in the biotechnology and pharmaceutical sectors. Prior to that, he worked at Dillon, Read & Co., specializing in health care mergers and acquisitions. Mr. Meyers earned a Bachelor of Science degree in finance from Boston College and a Master of Business Administration degree from Columbia Business School.
Lesley Russell, MBChB, MRCP
Chief Operating Officer
Dr. Russell is a hematologist/oncologist with more than 20 years of international pharmaceutical industry experience and leadership in the therapeutic areas of hematology/oncology, neurology, psychiatry, pain and inflammation, respiratory medicine, cardiovascular medicine and stem cell therapy. Dr. Russell was most recently Senior Vice President and Global Head, Research and Development, Global Branded Products for Teva Pharmaceuticals USA. She was appointed to this role upon Teva’s acquisition of Cephalon, Inc., where she served as Executive Vice President and Chief Medical Officer from 2006 to 2011. She joined Cephalon in 2000 as Vice President, Worldwide Clinical Research. Prior to Cephalon, she served as Vice President, Clinical Research at US Bioscience Inc. and held positions of increasing responsibility within the company from 1996 to 1999. From 1995 to 1996, she was a clinical research physician at Eli Lilly U.K. and a medical director at Amgen U.K. from 1992 to 1995. Dr. Russell was trained in hematology/oncology at Royal Infirmary of Edinburgh and at Royal Hospital for Sick Children, Edinburgh. She received an MBChB from the University of Edinburgh, Scotland, is a member of the Royal College of Physicians, United Kingdom and is registered with the General Medical Council, United Kingdom.
Richard L. Sherman, J.D.
Senior Vice President, Strategic Transactions and General Counsel
Mr. Sherman joined TetraLogic Pharmaceuticals in 2012 and previously provided consulting services to TetraLogic as Vice President, Strategic Partnering and Transactions at Malvern Consulting Group. He spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), was a partner in the law firm of Pepper Hamilton LLP (1990-1992), and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group in New York. He is a principal in a private SBIC Investment fund, CIP Capital, L.P. and a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia. Mr. Sherman has served on the Board of Directors of a number of for-profit companies, including Biophage, Inc., CytoMed, Inc., IBAH, Inc., Kenna Technologies, Inc., Mera Pharmaceuticals, Inc., and Sparta Pharmaceuticals. He is currently a member of the Board of Directors of Functional Technologies Corp., a Vancouver based publicly traded company, Hawaii Biotech, Inc. and Leversense LLC. Mr. Sherman graduated magna cum laude from the University of Nebraska (1968), where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he received his Juris Doctor in 1971.